In life sciences, speed and compliance aren’t optional, they’re mission-critical. Every delay in commercialization can cost millions, jeopardize launches, and ultimately impact patient access. At EVERSANA, we’ve reimagined the commercialization model with AI-powered solutions that deliver measurable impact: accelerating workflows, reducing costs, and ensuring regulatory rigor without compromise.
This commitment to innovation has earned EVERSANA recognition in PM360’s 2025 Innovation Issue, where two of our transformative platforms were featured for their ability to reshape the future of pharma operations.
AI Agency Platform (Artificial Intelligence Category)
The industry’s first fully integrated AI-driven agency solution, built with Google Cloud, transforms campaign development from weeks to minutes—delivering creative, compliant assets at unprecedented speed.
EVERSANA ORCHESTRATE™ PV (Core Business Processes Category)
An AI-enabled pharmacovigilance platform that accelerates literature monitoring and aggregate reporting, reducing costs by up to 60% while meeting global compliance standards.
These innovations aren’t just award-winning—they’re impact-driven. By leveraging AI to streamline critical workflows, our team empowers life sciences companies to launch smarter, faster, and more confidently than ever before.
Explore how EVERSANA’s AI Accelerator can accelerate your commercialization strategy.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…